Genetic reduction in ANGPTL3 and ANGPTL4 is associated with lower risk of chronic kidney disease (CKD) via enhanced lipoprotein lipase (LPL) activity, according to results of a drug target Mendelian randomisation (MR) study and single cell RNA sequencing analyses.
ANGPTL3 loss of function accelerates TRL lipolysis pathway
Fresh mechanistic insights into the impact of profound ANGPTL3 deficiency are provided in a study of apoB48, apoB100 and TG metabolism in chylomicrons, VLDL1, VLDL2, IDL and LDL in individuals with ANGPTL3 homozygous or heterozygous loss of function (LOF) variants, compared with controls.
Topline SHASTA-3 and SHASTA-4 results show durable TG reductions with plozasiran
The Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in patients with severe hypertriglyceridaemia (sHTG) have met their primary endpoint of TG reduction versus placebo and all prespecified secondary endpoints, including a statistically significant reduction in acute pancreatitis (AP) compared to placebo.
Risk weighted apoB improves CHD risk stratification
Risk weighted apoB (RW-apoB), a novel measure that integrates the particle number and atherogenic potential of LDL, triglyceride rich lipoprotein (TRL) and Lp(a), more accurately reflects total atherogenic burden and coronary heart disease (CHD) risk than LDL-C, non-HDL-C or apoB alone. This is the conclusion of Professor Jan Borén and colleagues from results with the […]
Tryngolza (olezarsen) is approved for sHTG in USA
The US Food and Drug Administration (FDA) has approved Tryngolza (olezarsen) as an adjunct to diet to reduce TG and the risk of acute pancreatitis in adults with severe hypertriglyceridaemia (sHTG), ie. TG ≥500 mg/dL.
Redemplo (plozasiran) receives EU approval for FCS treatment
Redemplo (plozasiran) has been approved by the European Commission (EC) for use as an adjunct to diet to reduce TG levels in adult patients diagnosed with familial chylomicronaemia syndrome (FCS) according to clinical criteria or genetic testing.





